Background: After removal of differentiated thyroid carcinoma (DTC), serum thyroglobulin (Tg) can indicate persistent or recurrent disease. We describe two novel two-step assays designed to measure low Tg concentrations. Methods: We evaluated prototypes of the new IRMA, DYNOtest ® Tg-pluS, and the new immunoluminometric assay (ILMA), LUMItest ® Tg-pluS. In the first step, a high-salt incubation buffer leads to dissociation of Tg-Tg antibody complexes in serum and is intended to reduce nonspecific interference and interference of potential Tg autoantibodies in the system. We studied recovery of human Tg (from thyroid glands) added to horse serum. We also studied 58 patients with DTC in whom Tg values under thyroid-stimulating hormone (TSH) suppression and TSH stimulation (without thyroxine) were available. 
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The major clinical application for thyroglobulin (Tg) 3 determination is the postoperative follow-up of patients with differentiated thyroid carcinoma (DTC), where any increase in serum Tg indicates residual thyroid tissue or persistent and recurrent disease (1) (2) (3) (4) . However, serum Tg measurements are one of the most difficult biochemical tests to maintain with high precision and reliability [see Spencer et al. (5 ) for a detailed review]. Several requirements are generally accepted for valid Tg determinations: high sensitivity, high interassay precision over a period of 6 -12 months, no high-dose hook effect when measuring very high Tg concentrations (e.g., to monitor therapy), and the introduction of a common standardization system (6 ) .
A particularly problematic issue is Tg detection in the serum of patients with Tg antibodies (Tg-Abs). Depending on the assay system, this can lead to either falsepositive or -negative values (5 ) . To detect interference in the Tg determination, a recovery test is usually performed using Tg, from thyroid glands, in concentrations of ϳ50 g/L. Measurements with disturbed recovery are discarded and will not be used for clinical decisions. This practice is strongly debated. Whereas several groups find recovery studies mandatory (7) (8) (9) (10) , others question the rational (11 ) on the basis of different Tg immunoreactivities between the Tg present in a patient's serum and the exogenous Tg from thyroid glands (12 ) . Assay interference might not be detected because of differences between serum Tg in cancer patients and the Tg used for recovery. However, a positive Tg result in serum with Tg-Abs is considered valuable clinical information by some researchers (4 ), but others are adamant about rejecting any Tg detection in the presence of antibodies, regardless of whether Tg is detectable (13 ) .
In the present study, we present two novel assays for Tg detection, using a stringent incubation protocol in high salt to reduce nonspecific and autoantibody-related interference. 
Materials and Methods

clinical information on patients
We studied 58 patients with DTC who were routinely scheduled for a posttherapy whole-body 131 I scan at the Nuclear Medicine outpatient department of the University Clinic Wuerzburg. Serum samples were taken before and after thyroxine (T 4 ) withdrawal. All patients had initially been treated by total thyroidectomy followed by radioablation. The interference of Tg-Abs was studied in 77 patients with autoimmune thyroid disease (Hashimoto thyroiditis and atropic thyroiditis). Dilution studies were performed on 12 sera from patients with metastatic thyroid cancer. Informed consent was obtained from all study participants.
assay principle
The DYNOtest Tg-pluS (IRMA) and LUMItest Tg-pluS (ILMA) are two-step assays for the quantitative detection of Tg in human serum. In the first step, 100 L of serum is added to tubes coated with affinity-purified rabbit polyclonal anti-Tg; 200 L of high-salt incubation buffer (50 mmol/L Tris, pH 6.8, 1.5 mol/L NaCl, 5.0 mL/L Triton X-100, 20 g/L bovine serum albumin) is then added to each tube. The tubes are incubated without shaking at room temperature overnight. The high NaCl concentration is used to dissociate complexes of Tg and anti-Tg antibodies in the patient serum and to reduce their interference in the assay. After the tubes are washed twice with washing buffer (B.R.A.H.M.S AG), they are incubated for 2 h at room temperature with shaking. For the IRMA, we used 200 L of a 125 I-labeled murine anti-Tg monoclonal antibody in buffer (50 mmol/L sodium phosphate, pH 6.8, 25 mmol/L NaCl, 2.0 mL/L Triton X-100, 10 g/L bovine serum albumin) as tracer. For the ILMA, we used 200 L of acridinium ester-labeled murine anti-Tg monoclonal antibody in the same buffer. After the tubes were washed three to four times, bound radioactivity was counted in a gamma counter for 1 min (IRMA) or the relative light units for the ILMA were detected in a luminometer. The cpm or relative light units were proportional to the Tg concentration of the patient serum.
Tg-Abs were determined in a commercially available competitive RIA, DYNOtest ® anti-Tg n (B.R.A.H.M.S AG). The cutoff for positivity is 60 kilounits/L.
calibrators and controls
Tg concentrations were calculated using a calibration curve derived from human thyroid gland Tg in horse serum. Calibrators were adjusted to the current Tg intraassay, interassay, and interlaboratory CVs The lower detection limit was 0.04 g/L Tg for the IRMA and 0.02 g/L for the ILMA. The intraassay CV (10 determinations per sample) was Ͻ10% over the range of the calibration curve for the IRMA ( Fig. 2A) and Ͻ5% for the ILMA (Fig. 2B) , respectively. The interassay CV was Յ20% (10 determinations per sample) for the IRMA at 0.1 g/L Tg with fresh tracer (not shown) and at 0.2 g/L Tg with tracer at the expiration date (Fig. 2C) . The interassay CV for the ILMA was Ͻ10% over the range of the calibration curve and Ͻ20% at 0.06 g/L (Fig. 2D) . The CV between different reagent lots (interlot CV, 10 determinations per sample) was determined by five operators using two counters and three reagent lots over a period of 12 months. All samples had a CV Ͻ12% (Fig. 2E) or Ͻ15% (Fig. 2F ), respectively.
cross-reactivity and reliability
There was no cross-reactivity to horse Tg up to a concentration of 100 000 g/L in either assay.
Assay linearity was confirmed using dilutions (1 part serum ϩ 1 part diluent to 1 part serum ϩ 31 parts diluent) of 10 different sera. All sera showed linear dilution in both assays, and the calculation of the original concentration in all dilutions was in agreement with the undiluted value. No pool effect was observed in the same 10 sera; the Tg determination in pooled sera produced the expected Tg concentrations.
no high-dose hook effect
To exclude a high-dose hook effect, Tg calibration material was diluted in human serum (highest concentration, 200 000 g/L). As shown in Fig. 3A , even at the highest values the calibration curve of the IRMA remained in the plateau and did not decrease to lower or even negative values. Additionally, a total of 12 patient serum samples with Tg values of 307-38 880 g/L were diluted and measured in the assay. All sera showed linear dilution in the IRMA without a high-dose hook effect (Fig. 3B) . Data for undiluted samples and 1:10 dilutions (1 part serum ϩ 9 parts diluent) for some sera were extrapolated from the calibration curve (Ͼ250 g/L). The precise Tg concentrations of these sera were calculated with the 1:100 (1 part serum ϩ 99 parts diluent) and 1:1000 (1 part serum ϩ 999 parts diluent) dilutions. Data for the ILMA were similar (not shown).
robustness and interferences
Both assays were robust with respect to changes in incubation temperature (17-29°C) and incubation time (18 Ϯ 4 h for the first incubation step, 2 h Ϯ 30 min for the second incubation step). To test whether the assays were influenced by hemolysis, serum lipids, or bilirubin, we diluted three sera in normal plasma, plasma containing lysed blood cells, plasma containing serum lipids, or plasma containing bilirubin. Both assays were unaffected by hemoglobin up to 60 g/L, serum lipids up to 3.2 g/L, or bilirubin up to 200 g/L.
comparison with established Tg assay Both new assays were compared with the DYNOtest Tg-S, using serum samples over the entire range of the calibration curve. Results of the regression analysis are shown in Fig. 4 . 
interference from Tg-Abs
Interference from Tg-Abs was tested in 77 sera that had tested positive for Tg-Abs (minimum, 65.2 kilounits/L; maximum, 8150 kilounits/L; median, 181 kilounits/L). Recovery (50 g/L) was disturbed in the ILMA in nine sera (12%), and in the IRMA in seven sera (9%), respectively. Of those sera, six were disturbed in both assays, one serum only in the IRMA, and three only in the ILMA (these three sera had a recovery of 69%). Recovery was considered undisturbed if measured Tg values were 70 -130% of the added Tg. Except for one serum in the IRMA, all sera with disturbed recoveries had Tg values Ͻ1 g/L (Fig. 5) and autoantibodies Ͼ800 kilounits/L (not shown).
Among the 116 samples from patients receiving or not receiving T 4 , the mean recovery in the IRMA was 96% (median, 97%).
Tg determination before and after T 4 withdrawal Evaluation of 58 paired thyroid cancer samples (with and without l-T 4 ) demonstrated an increase in Tg (greater than CV at the respective concentration) in 50 cases and constant values in 8 cases (Fig. 6) . Samples with Tg values below the functional assay sensitivity (FAS) should be considered undetectable.
Discussion
The determination of Tg in serum is an important diagnostic tool in the follow-up of patients with DTC. Assay requirements include a low detection limit and low imprecision at low Tg concentrations (14 ) . The new assays described here demonstrate the lowest detection limits reported to date. Furthermore, the interassay CV (also taking into account different laboratories) was Ͻ10% in the clinically important range of 0.5-1 g/L. T 4 withdrawal increased the detectable Tg in most thyroid cancer patients for whom low Tg values were measured, indicating that this low Tg was indeed secreted by residual thyroid tissue and that the result was not an assay artifact. The long-term precision for Tg Ͻ1 g/L allows prolonged clinical evaluation of patients with such low Tg concentrations. Although some physicians do not draw clinical conclusions from Tg values Ͻ1-2 g/L (15 ), the assay precision is excellent throughout the clinically relevant measuring range, potentially allowing improved monitoring.
Some physicians would prefer "less sensitive" assays because it is sometimes difficult to verify the source of very low Tg concentrations (Ͻ0.5 g/L) by additional imaging diagnostics, and confusion for the physician and the patient may occur (15 ) . Others, however, argue in favor of a complete evaluation of patients with detectable serum Tg, irrespective of the concentration (4 ). It is possible that very low Tg concentrations do not require immediate treatment. The changes in serum Tg over a certain period or after T 4 withdrawal are more informative than a single Tg determination (14 ) . This is of special clinical relevance when recombinant TSH is used for exogenous stimulation of thyroid tissue, which is not as intense as stimulation after T 4 withdrawal. Highly sensitive Tg assays that can distinguish a Tg increase from 0.2 to 0.8 g/L in one patient and confirm a constant low Tg of 0.8 g/L in another patient may be clinically valuable because only the first patient might need to undergo additional diagnoses or treatment. As increasingly sensitive assays become available and ultrasensitive methods such as PCR of Tg mRNA are considered (16, 17 ) , the Tg threshold or Tg increase at which clinical intervention should occur must be reevaluated in clinical studies.
Many IRMAs and ILMAs have the limitation of a high-dose hook effect (5 ), which is the result of "neutralization" of the tracer antibody by excess Tg, so that no sandwich complex is generated on the solid phase. An important improvement of the assays described here was the lack of such a high-dose hook effect in all samples with very high Tg concentrations.
Other Tg assays have tried to overcome the limitation of Tg determination in the presence of Tg-Abs, for example, by use of capture antibodies specific for certain Tg epitopes (18 ) . However, in clinical evaluations, interfer- ence by Tg-Abs was still reported (19 ) . In the two assays studied here, the frequencies of disturbed recovery in Tg-Ab-positive samples were considerably lower (12% for the ILMA, 9% for the IRMA) than have been reported in other systems [50 -68% (19 ) ].
The use of recovery to assess any interference in the Tg assay is supported by several groups (7) (8) (9) (10) who have found that the detection of Tg-Abs may not be sufficient for this purpose. Others favor Tg-Ab detection and consider recovery data in the presence of Tg-Abs invalid (4, 11 ) . Furthermore, the ratio between recovery Tg and sample Tg is an important factor. The use of 50 g/L Tg in recovery studies might not allow the detection of slight interferences by autoantibodies because the autoantibody concentration does not allow any conclusions on immunoreactivity with serum Tg. Thus, serum Tg values Ͻ5 g/L might not be detected, even if the recovery of 50 g/L is undisturbed (Ͼ70%). As a consequence, relapse or spreading of thyroid cancer could occur.
The conditions of the two-step assays (overnight incubation and 1.5 mol/L NaCl) increased the binding of Tg to the polyclonal capture antibodies, whereas nonspecific interference that might influence the assays was reduced. Furthermore, under these stringent conditions, complexes of Tg with anti-Tg antibodies are disrupted. As suggested by Mariotti et al. (19 ) , however, the problem of Tg detection in the presence of Tg-Abs may not be limited to assay problems. It may also reflect a faster clearance of the antigen-antibody complex from the patient in vivo, in which case the negative result in vitro may be analytically correct but is unable to exclude residual Tg-producing DTC tissue in the patient. Another point of criticism is the difference between serum Tg in patients and the Tg from thyroid glands used for recovery studies (12 ) . Finally, the difference between serum Tg isoforms in healthy individuals and patients with thyroid cancer may also be relevant (20 ) . We are currently evaluating whether a low-dose recovery consisting of 1 g/L serum Tg is able to alleviate some of these problems because it excludes structural and immunologic differences between serum Tg and colloidal Tg. Ongoing studies in a European multicenter trial will clarify whether this approach has a clinical benefit over the conventional recovery regime.
The excellent correlation of the new TG plus assay to the established and broadly used DYNOtest TG-S justifies the use of earlier Tg determinations in the same patient and makes additional measurements with stored serum samples less important. Despite the introduction of CRM 457 (6 ), a comparison of Tg values measured with different Tg assays is still difficult because no assay is calibrated 1:1 to the CRM (21 ) . Calibration of the DYNOtest Tg-pluS with the CRM 457 produced 50.1% activity. Thus, 1 ng of CRM 457 is equivalent to 0.5 ng in this assay.
In conclusion, we established IRMA and ILMA assays for Tg determination with low detection limits and excellent precision at Tg concentrations as low as 0.2 (or 0.06) g/L. Both assays are free of hook effects to the very high concentrations tested and appear to be less influenced by Tg-Abs. The clinical benefits of these new assays are currently under investigation in a European multi center trial. Data below the FAS should be considered undetectable.
